DIFIZMA is the only FDC dry powder inhalation product that has been approved by DCGI for the treatment of inadequately controlled asthma. The drug will be available in one strength with a fixed dose to be taken once daily. Gobal pharma major Lupin Limited has announced the launch of a novel fixed-dose triple drug combination (FDC) of Indacaterol, Glycopyrronium and Mometasone, under the brand name DIFIZMA in India, for managing inadequately controlled asthma among patients by improving lung function, providing better symptom control and reducing exacerbations. DIFIZMA is the only FDC dry powder inhalation (DPI) product combining Indacaterol, a long-acting beta-agonist, Glycopyrronium, a long-acting muscarinic receptor antagonist, and Mometasone Furoate, an inhaled corticosteroid, that has been approved by the Drug Controller General of India (DCGI) for the treatment of inadequately controlled asthma. The drug will be available in one strength with a fixed dose to be taken once daily Commenting on the launch, Rajeev Sibal, President, India Region Formulations, Lupin said,
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!